RxDoctor Payments Data

Oscar Guerra, MD

Cardiovascular Disease · Coral Gables, FLNPI 1801818232

Payments from drug & device makers

$10,246in general payments, 2019–2025

Across 20 payments — averaging $512.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$5K
  • GE HealthCare$4K
  • Heartflow, Inc.$353
  • Boston Scientific$288
  • Alnylam Pharmaceuticals Inc.$141
  • Azurity Pharmaceuticals, Inc.$73
  • plus $109 from 5 others

What the payments were for

  • Food & beverage$9329%
  • Education$310%
  • Other$9,28391%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,246 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$437,348
Medicare patients
1,269
Services billed
4,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban287$337,344
EntrestoSacubitril/Valsartan166$239,443
OzempicSemaglutide52$70,495
FarxigaDapagliflozin Propanediol40$61,085
Repatha SureclickEvolocumab52$43,276
JardianceEmpagliflozin33$35,670
MounjaroTirzepatide13$20,842
VascepaIcosapent Ethyl32$12,217
Valsartan298$9,952
Rosuvastatin Calcium405$9,485
Metoprolol Succinate362$7,726
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide124$5,594
Dexlansoprazole DrDexlansoprazole17$5,128
Atorvastatin Calcium278$3,867
SynthroidLevothyroxine Sodium23$3,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$15$239,443166 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →